IMV Inc. Commences Trading on the TSX and OTCQX Post-Reverse Stock Split
10 May 2018 - 9:05PM
IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVF), a
clinical stage immunotherapy company, announced that its common
shares commence trading post consolidation today.
As announced on May 3, 2018, the consolidation
has been done on the basis of one new common share for every 3.2
outstanding common shares. The consolidation has taken effect on
May 2, 2018, and the Corporation's common shares commence trading
on the Toronto Stock Exchange and on the OTCQX under the name IMV
Inc. on a post-consolidation basis at the open of markets
today.
About IMV
IMV Inc. is a clinical stage
biopharmaceutical company dedicated to making immunotherapy more
effective, more broadly applicable, and more widely available to
people facing cancer and other serious diseases. IMV is pioneering
a new class of immunotherapies based on the Company’s proprietary
drug delivery platform. This patented technology leverages a novel
mechanism of action that enables the reprogramming of immune cells
in vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently conducting three
Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a
combination therapy in ovarian cancer and diffuse large B-cell
lymphoma. Connect at www.imvaccine.com.
IMV Forward-Looking
Statements
This press release contains forward-looking
information under applicable Canadian and U.S. securities law. All
information that addresses activities or developments that we
expect to occur in the future is forward-looking information.
Forward-looking statements in this press release include, without
limitation, statements regarding the efficacy and availability of
immunotherapy. Although the Corporation believes the
forward-looking statements in this press release are reasonable, it
can give no assurance that the expectations and assumptions in such
statements will prove to be correct. The Corporation cautions
investors that any forward-looking statements by the Corporation
are not guarantees of future results or performance, and that
actual results may differ materially from those in forward-looking
statements as a result of various factors, including, but not
limited to, the matters discussed under “Risk Factors and
Uncertainties” in IMV’s Annual Information Form filed on
March 20, 2018. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown Inc. T: (312)
961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: Plabbe@imvaccine.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024